Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
Reaction mass of 2-{[3-(trimethoxysilyl)propyl]amino}ethanaminium chloride and 2-{benzyl[3-(trimethoxysilyl)propyl]amino}ethanaminium chloride and N-[2-(benzylamino)ethyl]-3-(trimethoxysilyl)propan-1-aminium chloride and N-[2-(dibenzylamino)ethyl]-3-(trimethoxysilyl)propan-1-aminium chloride and N-benzyl-2-{benzyl[3-(trimethoxysilyl)propyl]amino}ethanaminium chloride and N-benzyl-N-[2-(dibenzylamino)ethyl]-3-(trimethoxysilyl)propan-1-aminium chloride.
EC number: 700-961-2 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
Ames test (OECD TG 471, GLP): negative with and without metabolic
activation.
Chromosome aberration assay (OECD TG 473, GLP): negative with and
without metabolic activation.
Mouse Lymphoma Assay (OECD 476, GLP): negative with and without
metabolic activation.
Link to relevant study records
- Endpoint:
- in vitro gene mutation study in bacteria
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 22 June - 06 July 1992
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
- Remarks:
- The study was conducted according to OECD TG 471 with acceptable restrictions. The restriction was that no additional strain for the detection of crosslinking agents was included into the study. The study was further conducted in compliance with GLP.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- Version / remarks:
- (1983)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- Version / remarks:
- (1997)
- Deviations:
- yes
- Remarks:
- (no additional strain for the detection of crosslinking agents was included into the study)
- Qualifier:
- according to guideline
- Guideline:
- other: EU Method B.14 (Mutagenicity - Reverse Mutation Test Using Bacteria) (1984)
- Deviations:
- no
- GLP compliance:
- yes
- Type of assay:
- bacterial reverse mutation assay
- Target gene:
- his operon
- Species / strain / cell type:
- S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
- Metabolic activation:
- with and without
- Metabolic activation system:
- cofactor supplemented post-mitochondrial fraction (S9 mix), prepared from the livers of rats treated with Aroclor 1254.
- Test concentrations with justification for top dose:
- - experiment 1: 3.3, 10, 33, 100, 200 µg/plate
- experiment 2: 3.3, 10, 33, 100, 333 µg/plate - Vehicle / solvent:
- - Solvent used: DMSO (spectroscopic quality (Merck) to which molecular sieve (0.4 nm) beads (about 2 mm) were added to absorb the water)
- Justification for choice of solvent: The test article was found to be not stable in water - Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- other: -S9: sodium azide (SA; 1 µg/plate;TA1535); 9-aminoacridine (9AC; 60 µg/plate; TA1537); daunomycin (DM; 4 µg/plate; TA98); methylmethanesulfonate (MMS; 650 µg/plate; TA100);+S9: 2-aminoanthracene (2AA; 5 µg/plate:TA1535 and TA1537;0.5 µg/plate:TA98/TA100)
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: in agar (plate incorporation)
DURATION
- Preincubation period: none
- Exposure duration: 48 h
NUMBER OF REPLICATIONS: 3 replicates in 2 independent experiments
DETERMINATION OF CYTOTOXICITY
- Method: relative total growth (In a preliminary cytotoxicity experiment with TA100 both in absence and presence of metabolic activation nine concentrations of the test item were tested for cytotoxicity. The highest concentration of the test article used in the subsequent mutagenesis assay was that which gave a reduced survival on the non-selective plates.) - Evaluation criteria:
- A test substance is considered negative (not mutagenic) in the Ames test if:
- The total number of revertants in any tester strain at any concentration is not greater than two times the solvent control value, with or without metabolic activation.
- The negative response should be reproducible in at least one independently repeated experiment.
A test substance is considerd positive (mutagenic) in the Ames test if:
- It induces at leats a 2-fold, dose related increase in the number of revertants with respect to the number induced by the solvent control in any of the tester strains, either with or without metabolic activation. However, any mean plate count of less than 20 is considered to be not significant. If the test substance showed in the first test only a positive response at one or two concentrations, the assay was repeated with doses below and exceeding those showing positive effects in the first test.
- The positive response should be reproducible in at least one independently repeated experiment.
The preceding criteria were not absolute and other modifying factors might enter into the final evaluation decision. - Key result
- Species / strain:
- S. typhimurium TA 1535
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Positive controls validity:
- valid
- Key result
- Species / strain:
- S. typhimurium TA 1537
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Positive controls validity:
- valid
- Key result
- Species / strain:
- S. typhimurium TA 98
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Positive controls validity:
- valid
- Key result
- Species / strain:
- S. typhimurium TA 100
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Positive controls validity:
- valid
- Additional information on results:
- TEST-SPECIFIC CONFOUNDING FACTORS
- none
ADDITIONAL INFORMATION ON CYTOTOXICITY: The cytotoxicity of the test item was tested with TA100 in absence and presence of metabolic activation. In the presence of S9-mix the survival of strain TA100 is not reduced up to and including test substance concentrations of 33 µg/plate, slightly reduced at a concentration fo 100 µg/plate, extremely reduced at concentrations from 333 µg/plate up to and including 3330 µg/plate and absent at a concentration of 5000 µg/plate.
In the absence of S9-mix the survival of strain TA100 is not reduced up to and including test substance concentrations of 33 µg/plate, moderately reduced at a concentration fo 100 µg/plate, extremely reduced at a concentrations of 333 µg/plate and absent at test substance concentrations of 1000 µg/plate and upwards.
Based on these data, the test substance was tested up to and including a concentration of 200 µg/plate in the absence and presence of metabolic activation (experiment 1). In the first experiment no toxicity was observed, therefore it was decided to test up to and including a concentration of 333 µg/plate in the second experiment. - Conclusions:
- Interpretation of results: negative with and without metabolic activation
The test item was tested for mutagenicity to bacteria according to the OECD TG 471 (1983) and in compliance with GLP. No additional strain for the detection of crosslinking agents was included into the study. No test material related increase in revertants was observed up to cytotoxic concentrations. Hence, the test item is not mutagenic under the conditions of the study. - Endpoint:
- in vitro cytogenicity / chromosome aberration study in mammalian cells
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 15 July - 20 July 1992
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 473 (In Vitro Mammalian Chromosome Aberration Test)
- Version / remarks:
- (1983)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.10 (Mutagenicity - In Vitro Mammalian Chromosome Aberration Test)
- Version / remarks:
- (1984)
- Deviations:
- no
- GLP compliance:
- yes
- Type of assay:
- in vitro mammalian chromosome aberration test
- Target gene:
- not applicable
- Species / strain / cell type:
- lymphocytes: cultured peripheral human lymphocytes, provided by a healthy adult male volunteer (age 27)
- Details on mammalian cell type (if applicable):
- - Type and identity of media: F10 complete culture medium consisted of Ham's F10 medium without thymidine and hypoxanthine (Gibco), supplemented with 20% heat-inactivated (56 °C; 30 min) foetal calf serum (Gibco), L-glutamine (2 mM), penicilline/strptomycine (50 U/ml respectively), sodium bicarbonate (2 g/l), and heparine (30 U/ml).
- Metabolic activation:
- with and without
- Metabolic activation system:
- S9-homogenate of male rats
- Test concentrations with justification for top dose:
- - without S9: 100, 133, and 180 µg/ml culture medium (24 h fixation period), and 237 µg/ml culture medium (48 h fixation period)
- with S9: 180, 237, and 333 µg/ml culture medium (24 h fixation period), and 333 µg/ml culture medium (48 h fixation period) - Vehicle / solvent:
- - Solvent used: DMSO (spectroscopic quality (Merck) to which molecular sieve (0.4 nm) beads (about 2 mm) were added to absorb the water)
- Justification for choice of solvent: The test article was found to be not stable in water - Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- mitomycin C
- Remarks:
- without metabolic activation: (MMC-C) 0.2 µg/ml in HBSS (24 h treatment) and 0.1 µg/ml in HBSS (48 h treatment)
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- cyclophosphamide
- Remarks:
- with metabolic activation: (CP) 15 µg/ml in HBSS (3 h treatment)
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: in medium
DURATION
- Exposure duration: 24 and 48 h (without metabolic activation), 3 h (with metabolic activation)
- Fixation time (start of exposure up to fixation or harvest of cells): 24 and 48 h
SPINDLE INHIBITOR (cytogenetic assays): colchicine (0.5 µg/ml medium)
STAIN (for cytogenetic assays): Giemsa solution in tap water
NUMBER OF REPLICATIONS: 2
NUMBER OF CELLS EVALUATED: at least 100 metaphase chromosome spreads per culture
DETERMINATION OF CYTOTOXICITY
- Method: The mitotic index was determined in a pilot study carried out for the purpose of dose selection (24 and 48 h fixation period). The tested doses were: 33, 100, 133, 180, and 237 µg/ml without metabolic activation, and 33, 100, 180, 237, and 333 µg/ml with metabolic activation. - Evaluation criteria:
- A test substance was considered positive (clastogenic) in the chromosome aberration test if:
- it induced a dose-related statistically significant (Chi-square test, p < 0.05) increase in the number of cells with chromosome aberrations.
- a satistically significant increase in the frequency of aberrations was observed in the absence of a clear dose-response relationship, but the results were reproducible in an independently repeated experiment.
A test substance is considered negative (non-clasogenic) in the chromosome aberration test if:
- none of the tested concentrations induced a statistically significant increase (Chi-square test, p < 0.05) in the number of cells with chromosome aberrations.
The preceding criteria were not absolute and other modifying factors might enter into the final evaluation decision. - Statistics:
- The incidence of aberrant cells (cells with one or more chromosome aberrations, inclusive or exclusive gaps) for each treatment group was compared to that of the solvent control using Chi-square statistics.
If p (two-tailed) is small (< 0.05) the hypothesis that the incidence of cells with chromosome aberrations is the same for both the treated and the solvent control is rejected and the number of aberrant cells in the test group is considered to be significantly different from the control group at the 95% confidence level. - Species / strain:
- lymphocytes: cultured peripheral human lymphocytes, privided by a healthy adult male volunteer (age 27)
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Positive controls validity:
- valid
- Additional information on results:
- TEST-SPECIFIC CONFOUNDING FACTORS
- none
RANGE-FINDING/SCREENING STUDIES: A pilot study was carried out for dose selection based on cytotoxicity of the test item (reduction of the mitotic index).
COMPARISON WITH HISTORICAL CONTROL DATA: The number of cells with chromosome aberrations found in the solvent control cultures fell within the laboratory historical control data range.
VALIDITY OF THE TEST: The positive control chemicals (MMC-C and CP) both produced significant increases in the frequency of aberrant cells. It was therefore concluded that the test conditions were optimal and that the metabolic activation system (S9 mix) functioned properly.
Finally it is concluded that this test should be considered valid. - Conclusions:
- Interpretation of results: negative with and without metabolic activation
The test item was tested forclastogenicity to cultured human peripheral lymphocytes according to the OECD TG 473 (1983) and in compliance with GLP. The test item was concluded not clastogenic with and without metabolic activation under the experimental conditions of this test. - Endpoint:
- in vitro gene mutation study in mammalian cells
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2012-08-22 to 2012-11-27
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- The study was conducted according to the appropriate OECD test guideline, and in compliance with GLP. No data on test material purity is given in the report. However, a certificate of analysis is included, but the data are not sufficient to calculate the purity, since the submission substance is a multiconstituent.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 476 (In Vitro Mammalian Cell Gene Mutation Test)
- Deviations:
- yes
- Remarks:
- (no data on test material purity given)
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.17 (Mutagenicity - In Vitro Mammalian Cell Gene Mutation Test)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.5300 - In vitro Mammalian Cell Gene Mutation Test
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: IWGT Recommendations
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- (Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit, Germany)
- Type of assay:
- in vitro mammalian cell gene mutation tests using the thymidine kinase gene
- Target gene:
- TK locus
- Species / strain / cell type:
- mouse lymphoma L5178Y cells
- Details on mammalian cell type (if applicable):
- - Type and identity of media: RPMI
- Properly maintained: Yes
- Periodically checked for Mycoplasma contamination: yes
- Periodically "cleansed" against high spontaneous background: yes - Metabolic activation:
- with and without
- Metabolic activation system:
- Liver S9 of Wistar Phenobarbital and ß-Naphthoflavone-induced rat liver S9 mix
- Test concentrations with justification for top dose:
- - Pre-Experiment I (with and without metabolic activation): 50, 150, 500, 1000, 2000, and 5000 µg/ml
- Pre-Experiment II (24 h long-term exposure assay, without metabolic activation): 1, 5, 10, 20, 50, and 80 µg/ml
- Experiment I with metabolic activation: 1.5, 3, 7, 15, 30, 75, 150, and 200 µg/ml and without metabolic activation: 1.5, 3, 7, 15, 40, 55, 70, and 85 µg/ml
- Experiment II with metabolic activation: 8, 16, 35, 70, 160, 170, 180, and 210 µg/ml and without metabolic activation: 2, 5, 10, 20, 30, 45, 50, and 55 µg/ml - Vehicle / solvent:
- Due to the nature of the test item it was not possible to prepare a solution of the test item with an appropriate solvent. Based on the results of the solubility test the best suited vehicle was RPMI cell culture medium (RPMI+5% HS). The suspension was treated with ultrasonication for 5 minutes at 37°C and after that the suspension was dispersed.
The vehicle was compatible with the survival of the cells of the S9 activity. - Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- benzo(a)pyrene
- ethylmethanesulphonate
- methylmethanesulfonate
- Remarks:
- +S9: benzo(a)pyrene (B[a]P) 1.5 and 2.5 µg/ml; -S9: ethylmethanesulphonate (EMS) 200 and 300 µg/ml, methylmethanesulphonate (MMS) 8 and 10 µg/ml
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: in medium
DURATION: 4 h (short-term exposure), 24 h (long-term exposure)
Expression time (cells in growth medium): 48 h
Selection time (if incubation with selection agent): about 14 days
SELECTION AGENT ( mutation assay) 5 µg/ml trifluorothymidine
NUMBER OF REPLICATIONS: two separate experiments (I+II) with single exposure; cells were seeded in 4 plates and evaluated
NUMBER OF CELLS SEEDED: 2000 cells per well
DETERMINATION OF CYTOTOXICITY: relative total growth (RTG) - Evaluation criteria:
- The test item is considered mutagenic if following criteria are met:
-The induced mutant frequency meets or exceeds the Global Evaluation factor (GEF) of 126 mutants per 10^6 cells
- A dose-dependent increase in mutant frequency is detected.
Besides, combined with a positive effect in the mutant frequency, an increased occurrence of small colonies (≥40% of total colonies) is an indication for potential clastogenic effects and/or chromosomal aberrations.
According to the OECD guideline, the biological relevance is considered first for the interpretation of results. Statistical methods might be used as an aid in evaluation the test result.
A test item is considered to be negative if the induced mutant frequency is below the GEF and the trend test is negative. - Statistics:
- The non-parametric Mann-Whitney test is applied to the mutation data to prove the dose groups for any significant difference in mutant frequency compared to the negative /solvent controls.
- Species / strain:
- mouse lymphoma L5178Y cells
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- +S9: 200 µg/ml and above; -S9: 55 µg/ml and above (4 h), 30 µg/ml and above (24 h)
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Positive controls validity:
- valid
- Additional information on results:
- TEST-SPECIFIC CONFOUNDING FACTORS
- Effects of pH: no effect observed
- Effects of osmolality: no effect observed
- Solubility: Due to the nature of the test item it was not possible to prepare a solution of the test item with an appropriate solvent. Therefore, the test iteam was applied as a suspension in RPMI cell culture medium (RPMI+5% HS).
- Precipitation: not observed
COMPARISON WITH HISTORICAL CONTROL DATA:
The mutant frequencies obtained from the experiments were compared with the Global Evaluation Factor, which is defined as the mean of the negative / vehicle mutant frequencies gathered from 10 participating laboratories plus one standard deviation. The GEF is 126 for the applied microwell method. - Conclusions:
- Interpretation of results: negative
The test item was tested for in vitro mutagenicity in the Mouse Lymphoma Assay. The study was conducted according to the OECD test guideline 476, and in compliance with GLP. In conclusion, in the described mutagenicity test under the experimental conditions reported, the test item Reaction mass of 6 benzylated amine silanes (ELINCS 414-340-6) is considered to be non-mutagenic in the in vitro mammalian cell gene mutation assay (thymidine kinase locus) in mouse lymphoma L5178Y cells.
Referenceopen allclose all
Tab. 1: Mutagenic response of ORGANOFUNCTIONAL SILANE A-1128 in the Ames Salmonella/microsome plate test. Given is the mean number of revertant (His+) colonies / 3 replicate plates (± SD) with different strains of S. typhimurium (experiment 1).
Dose [µg/plate] |
TA1535 |
TA1537 |
TA100 |
TA98 |
|||||
+ S9 |
- S9 |
+ S9 |
- S9 |
+ S9 |
- S9 |
+ S9 |
- S9 |
||
Test item |
3.3 |
17 ± 5 |
16 ± 1 |
7 ± 3 |
6 ± 2 |
29 ± 6 |
21 ± 1 |
97 ± 7 |
88 ± 8 |
10 |
20 ± 5 |
17 ± 3 |
6 ± 1 |
3 ± 2 |
27 ± 3 |
20 ± 2 |
97 ± 4 |
85 ± 10 |
|
33 |
15 ± 5 |
15 ± 4 |
6 ± 1 |
4 ± 2 |
28 ± 1 |
21 ± 5 |
105 ± 4 |
85 ± 12 |
|
100 |
16 ± 2 |
15 ± 6 |
9 ± 2 |
6 ± 1 |
29± 6 |
25 ± 3 |
112 ± 6 |
87 ± 1 |
|
200 |
12 ± 3 |
9 ± 2 |
9 ± 1 |
6 ± 2 |
26 ± 6 |
22 ± 2 |
113 ± 6 |
75 ± 21 |
|
Solvent control |
14 ± 1 |
19 ± 1 |
11 ± 1 |
4 ± 2 |
30 ± 5 |
22 ± 4 |
87 ± 6 |
89 ± 8 |
|
Positive control |
282 ± 49 |
273 ± 15 |
902 ± 64 |
154 ± 22 |
362 ± 25 |
321 ± 34 |
585 ± 71 |
844 ± 99 |
Tab. 2: Mutagenic response of ORGANOFUNCTIONAL SILANE A-1128 in the Ames Salmonella/microsome plate test. Given is the mean number of revertant (His+) colonies / 3 replicate plates (± SD) with different strains of S. typhimurium (experiment 2).
Dose [µg/plate] |
TA1535 |
TA1537 |
TA100 |
TA98 |
|||||
+ S9 |
- S9 |
+ S9 |
- S9 |
+ S9 |
- S9 |
+ S9 |
- S9 |
||
Test item |
3.3 |
7 ± 2 |
9 ± 3 |
8 ± 3 |
6 ± 1 |
33 ± 2 |
32 ± 4 |
88 ± 7 |
80 ± 8 |
10 |
7 ± 1 |
10 ± 4 |
8 ± 5 |
6 ± 3 |
30 ± 3 |
25 ± 3 |
84 ± 5 |
69 ± 3 |
|
33 |
11 ± 2 |
9 ± 2 |
8 ± 3 |
5 ± 2 |
30 ± 8 |
22 ± 7 |
84 ± 8 |
63 ± 20 |
|
100 |
11 ± 3 |
13 ± 1 |
10 ± 6 |
7 ± 1 |
32± 1 |
28 ± 6 |
100 ± 19 |
84 ± 10 |
|
333 |
12 ± 2 |
6 ± 5 |
5 ± 2 |
3 ± 1 |
25 ± 5 |
19 ± 9 |
70 ± 2 |
40 ± 8 |
|
Solvent control |
10 ± 1 |
8 ± 1 |
6 ± 2 |
7 ± 2 |
30 ± 6 |
27 ± 4 |
92 ± 26 |
80 ± 10 |
|
Positive control |
252 ± 59 |
198 ± 28 |
1008 ± 10 |
145 ± 7 |
493 ± 20 |
443 ± 68 |
576 ± 13 |
1030 ± 18 |
Tab. 1: Chromosome aberration in donor cultures treated with various concentrations of the test item in the absence of metabolic activation.
Concentration |
24 h fixation period |
48 h fixation period |
||||||||||||||||||||||
|
DMSO (0.9% v/v) |
100 µg/ml |
133 µg/ml |
180 µg/ml |
MMC-C 0.2 µg/ml |
DMSO (0.9% v/v) |
237 µg/ml |
MMC-C 0.1 µg/ml |
||||||||||||||||
Culture |
A |
B |
A + B |
A |
B |
A + B |
A |
B |
A + B |
A |
B |
A + B |
A |
B |
A + B |
A |
B |
A + B |
A |
B |
A + B |
A |
B |
A + B |
No. of cells scored |
100 |
100 |
200 |
100 |
100 |
200 |
100 |
100 |
200 |
100 |
100 |
200 |
100 |
100 |
200 |
100 |
100 |
200 |
100 |
100 |
200 |
100 |
100 |
200 |
No. of cells with aberrations (+ gaps) |
6 |
3 |
9 |
0 |
1 |
1 |
2 |
2 |
4 |
2 |
1 |
3 |
44 |
25 |
69 |
2 |
2 |
4 |
2 |
1 |
3 |
42 |
51 |
93 |
No. of cells with aberrations (- gaps) |
1 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
33 |
21 |
54 |
0 |
0 |
0 |
1 |
0 |
1 |
28 |
40 |
68 |
Chromatid gap |
8 |
3 |
|
|
1 |
|
2 |
2 |
|
2 |
1 |
|
19 |
6 |
|
2 |
2 |
|
1 |
1 |
|
24 |
21 |
|
Chromosome gap |
|
|
|
|
|
|
|
|
|
|
|
|
3 |
3 |
|
|
|
|
|
|
|
4 |
|
|
Chromatid break |
1 |
|
|
|
|
|
|
|
|
|
|
|
26 |
16 |
|
|
|
|
1 |
|
|
17 |
27 |
|
Chromosome break |
|
|
|
|
|
|
|
|
|
|
|
|
6 |
3 |
|
|
|
|
|
|
|
4 |
2 |
|
Chromatid deletion |
|
|
|
|
|
|
|
|
|
|
|
|
1 |
|
|
|
|
|
|
|
|
4 |
|
|
Tab. 2: Chromosome aberration in donor cultures treated with various concentrations of the test item in the presence of metabolic activation.
Concentration |
24 h fixation period |
48 h fixation period |
|||||||||||||||||||
|
DMSO (0.9% v/v) |
180 µg/ml |
237 µg/ml |
333 µg/ml |
CP 15 µg/ml |
DMSO (0.9% v/v) |
333 µg/ml |
||||||||||||||
Culture |
A |
B |
A + B |
A |
B |
A + B |
A |
B |
A + B |
A |
B |
A + B |
A |
B |
A + B |
A |
B |
A + B |
A |
B |
A + B |
No. of cells scored |
100 |
100 |
200 |
100 |
100 |
200 |
100 |
100 |
200 |
100 |
100 |
200 |
100 |
100 |
200 |
100 |
100 |
200 |
100 |
100 |
200 |
No. of cells with aberrations (+ gaps) |
4 |
1 |
5 |
4 |
0 |
4 |
1 |
2 |
3 |
4 |
1 |
5 |
28 |
32 |
60 |
1 |
2 |
3 |
3 |
3 |
6 |
No. of cells with aberrations (- gaps) |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
0 |
0 |
0 |
25 |
26 |
51 |
1 |
0 |
1 |
0 |
0 |
0 |
Chromatid gap |
3 |
1 |
|
4 |
|
|
1 |
1 |
|
4 |
1 |
|
14 |
16 |
|
|
2 |
|
3 |
3 |
|
Chromosome gap |
1 |
|
|
1 |
|
|
|
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
Chromatid break |
|
|
|
|
|
|
|
1 |
|
|
|
|
18 |
26 |
|
|
|
|
|
|
|
Chromosome break |
|
|
|
|
|
|
|
|
|
|
|
|
|
7 |
|
|
|
|
|
|
|
Chromatid deletion |
|
|
|
|
|
|
|
|
|
|
|
|
1 |
1 |
|
|
|
|
|
|
|
Tab. 1: Main Experiment I – 4 h exposure duration with metabolic activation
Test group |
Concentration [µg/ml] |
RTG1 [%] |
MF2 [mutants/1E+6 cells] |
IMF3 [mutants/1E+6 cells] |
small colonies [%] |
Solvent control |
0 |
100 |
82.3 |
- |
6.7 |
69.9 |
- |
12.2 |
|||
Test item |
1.5 |
88.5 |
103.5 |
27.4 |
n.d. |
3 |
81.1 |
96.7 |
20.6 |
n.d. |
|
7 |
109.3 |
70.5 |
-5.6 |
n.d. |
|
15 |
98.4 |
84.5 |
8.4 |
n.d. |
|
30 |
87.5 |
108.1 |
32.0 |
n.d. |
|
75 |
73.8 |
100.2 |
24.1 |
14.8 |
|
150 |
71.7 |
65.6 |
-10.5 |
14.9 |
|
200 |
11.0 |
98.8 |
22.7 |
14.8 |
|
B[a]P |
2.5 |
35.6 |
446.0 |
369.9 |
40.8 |
Tab. 2: Main Experiment I – 4 h exposure duration without metabolic activation
Test group |
Concentration [µg/ml] |
RTG1 [%] |
MF2 [mutants/1E+6 cells] |
IMF3 [mutants/1E+6 cells] |
small colonies [%] |
Solvent control |
0 |
100 |
53.7 |
- |
23.6 |
62.1 |
- |
27.3 |
|||
Test item |
1.5 |
75.5 |
50.5 |
-7.4 |
n.d. |
3 |
80.4 |
36.6 |
-21.3 |
n.d. |
|
7 |
78.6 |
41.1 |
-16.8 |
n.d. |
|
15 |
74.9 |
38.9 |
-19.0 |
n.d. |
|
40 |
59.4 |
49.0 |
-8.9 |
n.d. |
|
55 |
29.8 |
55.1 |
-2.8 |
13.5 |
|
70 |
16.2 |
47.0 |
-10.9 |
33.3 |
|
85 |
11.6 |
72.1 |
14.2 |
9.3 |
|
EMS |
300 |
56.9 |
465.3 |
407.3 |
n.d. |
MMS |
10 |
32.1 |
462.6 |
404.7 |
50.0 |
Tab. 3: Main Experiment II – 4 h exposure duration with metabolic activation
Test group |
Concentration [µg/ml] |
RTG1 [%] |
MF2 [mutants/1E+6 cells] |
IMF3 [mutants/1E+6 cells] |
small colonies [%] |
Solvent control |
0 |
100 |
89.1 |
- |
9.8 |
68.9 |
- |
4.1 |
|||
Test item |
8 |
115.5 |
71.0 |
-8.0 |
n.d. |
16 |
95.5 |
83.2 |
4.2 |
n.d. |
|
35 |
103.6 |
71.1 |
-7.8 |
n.d. |
|
70 |
94.5 |
91.0 |
12.0 |
n.d. |
|
160 |
97.2 |
67.7 |
-11.3 |
n.d. |
|
170 |
90.2 |
56.1 |
-22.9 |
5.4 |
|
180 |
66.1 |
91.0 |
12.0 |
7.5 |
|
210 |
18.0 |
70.7 |
-8.3 |
16.3 |
|
B[a]P |
1.5 |
77.6 |
420.1 |
341.1 |
44.2 |
Tab. 4: Main Experiment II – 24 h exposure duration without metabolic activation
Test group |
Concentration [µg/ml] |
RTG1 [%] |
MF2 [mutants/1E+6 cells] |
IMF3 [mutants/1E+6 cells] |
small colonies [%] |
Solvent control |
0 |
100 |
78.8 |
- |
8.5 |
62.2 |
- |
8.3 |
|||
Test item |
2 |
92.3 |
66.6 |
-4.0 |
n.d. |
5 |
111.4 |
58.6 |
-11.9 |
n.d. |
|
10 |
79.2 |
55.8 |
-14.7 |
n.d. |
|
20 |
76.1 |
60.7 |
-9.8 |
n.d. |
|
30 |
43.8 |
54.8 |
-15.7 |
n.d. |
|
45 |
39.3 |
55.9 |
-14.7 |
11.1 |
|
50 |
30.9 |
68.9 |
-1.6 |
12.8 |
|
55 |
20.1 |
70.9 |
0.4 |
3.9 |
|
EMS |
200 |
27.1 |
2239.3 |
2168.8 |
n.d. |
MMS |
8 |
37.9 |
849.8 |
779.3 |
47.6 |
1RTG=Relative Total Growth
2MF=Mutant Frequency={-ln[solvent control cultures/total wells (selective medium)]/-ln[solvent control cultures/total wells (non-selective medium)]}x800
3MF=Induced Mutant Frequency=mutant frequency sample-mean value mutant frequency corresponding controls
n.d.=not determined
B[a]P= Benzo[a]pyrene, EMS=Ethylmethanesulfonate, MMS=Methylmethanesulfonate
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Genetic toxicity in vivo
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
In vitro:
An Ames test according to OECD TG 471 (adopted 1983) and in compliance with GLP was performed to assess the mutagenic properties of the test substance (NOTOX, 1992a). S. typhimurium TA 1535, TA 1537, TA 98, and TA 100 were treated with 3.3-333 µg/plate of the test substance in the presence or absence of a metabolic activation system. No increase of the mutation frequency was observed in any tester strain at any dose level. No toxicity and no precipitation were observed up to 200 µg/plate in the first of 2 experiments, thus testing with up to 333 µg/plate was conducted in the second experiment. The negative and positive controls were valid. In contrast to the actual guideline, which recommends the use of an additional strain for testing of cross-linking substances, only 4 strains were used in this test, limiting the informative value. In conclusion, the test substance is not proposed to be mutagenic under the conditions of this test.
In a second in vitro test, performed according to OECD TG 473 and in compliance with GLP, the test substance was investigated on its ability to induce chromosome aberrations (NOTOX, 1992b). Cultured peripheral human lymphocytes were treated for 3 hours with 180, 237, and 333 µg/ml culture medium (24 h fixation period), and 333 µg/ml culture medium (48 h fixation period) in the presence of metabolic activation. In the absence of metabolic activation the cells were treated with 100, 133, and 180 µg/ml culture medium (24 h fixation period), and 237 µg/ml culture medium (48 h fixation period) until fixation. No genotoxic effects were observed within the study. Appropriate solvent and positive controls were included and showed expected results. The test substance is considered to be not genotoxic under the test conditions applied.
In the third available in vitro test (BSL, 2013), performed according to OECD TG 476, and in compliance with GLP, the test item was assessed for its potential to induce mutations at the mouse lymphoma thymidine kinase locus using the cell line L5178Y. The selection of the concentrations used in the main experiments was based on cytotoxicity data from the pre-experiments. In experiment I 200 μg/ml (with metabolic activation) and 85 µg/ml (without metabolic activation) were selected as the highest concentrations. In experiment II 210 µg/ml (with metabolic activation) and 55 µg/ml (without metabolic activation) were selected as the highest concentrations. Experiment I with and without metabolic activation and experiment II with metabolic activation were performed as a 4 h short-term exposure assay. Experiment II without metabolic activation was performed as a 24 h long-term exposure assay. Due to the nature of the test item it was not possible to prepare a solution of the test item with an appropriate solvent. Therefore, the test item was applied as a suspension in RPMI cell culture medium (RPMI+5% HS). No precipitation of the test item was noted in the experiments. Growth inhibition was observed in experiment I and II with and without metabolic activation. In experiment I with metabolic activation the relative total growth (RTG) was 11.0% for the highest concentration (200 µg/ml) evaluated. The highest concentration evaluated without metabolic activation was 85 µg/ml with a RTG of 11.6%. In experiment II with metabolic activation the relative total growth (RTG) was 18.0% for the highest concentration (210 µg/ml) evaluated. The highest concentration evaluated without metabolic activation was 55 µg/ml with a RTG of 20.1%. In experiment I and II no biologically relevant increase of mutants was found after treatment with the test item (with and without metabolic activation). The Global Evaluation Factor (GEF; defined as the mean of the negative/vehicle mutant frequency plus one standard deviation; data gathered from ten laboratories) was not exceeded by the induced mutant frequency at any concentration. In addition no dose-response relationship was observed. Additionally, in experiment I and II colony sizing showed no clastogenic effects induced by the test item under the experimental conditions (with and without metabolic activation). Appropriate solvent and positive controls were included into the test and gave the expected results. The test item is therefore concluded to be not mutagenic to mammalian cells in vitro under the conditions of the test.
In vivo:
No data available.
Justification for classification or non-classification
The available in vitro genotoxicity data are reliable and suitable for classification. Based on this data, classification for mutagenicity according to Regulation 67/584/EEC and (EC)1272/2008 is not warranted.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.